Display options
Cite
Seto K, Shoda J, Horibe T, et al. Targeting interleukin-4 receptor alpha by hybrid Peptide for novel biliary tract cancer therapy. Int J Hepatol. 2014;2014:584650doi: 10.1155/2014/584650.
Seto, K., Shoda, J., Horibe, T., Warabi, E., Kohno, M., Yanagawa, T., Bukawa, H., Nakanuma, Y., & Kawakami, K. (2014). Targeting interleukin-4 receptor alpha by hybrid Peptide for novel biliary tract cancer therapy. International journal of hepatology, 2014584650. https://doi.org/10.1155/2014/584650
Seto, Kahori, et al. "Targeting interleukin-4 receptor alpha by hybrid Peptide for novel biliary tract cancer therapy." International journal of hepatology vol. 2014 (2014): 584650. doi: https://doi.org/10.1155/2014/584650
Seto K, Shoda J, Horibe T, Warabi E, Kohno M, Yanagawa T, Bukawa H, Nakanuma Y, Kawakami K. Targeting interleukin-4 receptor alpha by hybrid Peptide for novel biliary tract cancer therapy. Int J Hepatol. 2014;2014:584650. doi: 10.1155/2014/584650. Epub 2014 Apr 27. PMID: 24868471; PMCID: PMC4020457.
Copy Download .nbib Format: NLM
Share it on

Int J Hepatol. 2014;2014:584650. doi: 10.1155/2014/584650. Epub 2014 Apr 27.

Targeting interleukin-4 receptor alpha by hybrid Peptide for novel biliary tract cancer therapy.

International journal of hepatology

Kahori Seto, Junichi Shoda, Tomohisa Horibe, Eiji Warabi, Masayuki Kohno, Toru Yanagawa, Hiroki Bukawa, Yasuni Nakanuma, Koji Kawakami

Affiliations

  1. Department of Oral and Maxillofacial Surgery, Clinical Sciences, University of Tsukuba, Ibaraki 305-8575, Japan ; Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Yoshida Konoe-cho, Sakyo-ku, Kyoto 606-8501, Japan.
  2. Medical Science, Faculty of Medicine, University of Tsukuba, Ibaraki 305-8575, Japan.
  3. Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Yoshida Konoe-cho, Sakyo-ku, Kyoto 606-8501, Japan.
  4. Division of Biomedical Science, Faculty of Medicine, University of Tsukuba, Ibaraki 305-8575, Japan.
  5. Department of Oral and Maxillofacial Surgery, Clinical Sciences, University of Tsukuba, Ibaraki 305-8575, Japan.
  6. Department of Human Pathology, Graduate School of Medical Science, Kanazawa University, Kanazawa 920-1192, Japan.

PMID: 24868471 PMCID: PMC4020457 DOI: 10.1155/2014/584650

Abstract

It is known that the interleukin-4 receptor α (IL-4R α ) is highly expressed on the surface of various human solid tumors. We previously designed novel IL-4R α -lytic hybrid peptide composed of binding peptide to IL-4R α and cell-lytic peptide and reported that the designed IL-4R α -lytic hybrid peptide exhibited cytotoxic and antitumor activity both in vitro and in vivo against the human pancreatic cancer cells expressing IL-4R α . Here, we evaluated the antitumor activity of the IL-4R α -lytic hybrid peptide as a novel molecular targeted therapy for human biliary tract cancer (BTC). The IL-4R α -lytic hybrid peptide showed cytotoxic activity in six BTC cell lines with a concentration that killed 50% of all cells (IC50) as low as 5  μ M. We also showed that IL-4R α -lytic hybrid peptide in combination with gemcitabine exhibited synergistic cytotoxic activity in vitro. In addition, intravenous administration of IL-4R α -lytic hybrid peptide significantly inhibited tumor growth in a xenograft model of human BTC in vivo. Taken together, these results indicated that the IL-4R α -lytic hybrid peptide is a potent agent that might provide a novel therapy for patients with BTC.

References

  1. Biochem Biophys Res Commun. 2011 Oct 14;414(1):60-6 - PubMed
  2. Lancet Oncol. 2010 Dec;11(12):1142-8 - PubMed
  3. Int J Oncol. 1998 Dec;13(6):1269-74 - PubMed
  4. Oncol Rep. 2013 Jun;29(6):2147-53 - PubMed
  5. Hepatology. 2001 Jun;33(6):1353-7 - PubMed
  6. BMC Cancer. 2011 Aug 18;11:359 - PubMed
  7. Curr Opin Immunol. 1999 Oct;11(5):570-8 - PubMed
  8. J Transl Med. 2011 Jan 14;9:8 - PubMed
  9. J Neurooncol. 2003 Aug-Sep;64(1-2):125-37 - PubMed
  10. Drug Discov Today. 2011 Jun;16(11-12):495-503 - PubMed
  11. Int J Cancer. 2011 Mar 1;128(5):1221-31 - PubMed
  12. Eur J Cancer. 2011 Mar;47(5):773-83 - PubMed
  13. Biochem Biophys Res Commun. 2011 Apr 8;407(2):383-8 - PubMed
  14. Gut. 2001 Jun;48(6):816-20 - PubMed
  15. Cancer Chemother Pharmacol. 2006 May;57(5):647-53 - PubMed
  16. Cancer. 1992 Apr 1;69(7):1664-73 - PubMed
  17. World J Gastroenterol. 2005 May 14;11(18):2748-53 - PubMed
  18. J Immunother. 2006 Mar-Apr;29(2):208-14 - PubMed
  19. Mol Cancer Ther. 2012 Jan;11(1):235-43 - PubMed
  20. Cancer Res. 2007 Oct 15;67(20):9903-12 - PubMed
  21. World J Gastroenterol. 2005 Jun 14;11(22):3392-7 - PubMed
  22. N Engl J Med. 2010 Apr 8;362(14):1273-81 - PubMed
  23. Am J Clin Oncol. 2008 Apr;31(2):140-4 - PubMed
  24. Int J Cancer. 2008 Dec 15;123(12):2915-22 - PubMed
  25. J Hepatol. 1985;1(6):579-96 - PubMed

Publication Types